Castle Biosciences
Valuation each multiple against its own 5-year range
Vs. peers Diagnostics & Research
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| Castle Biosciences (CSTL) | 1.01B | -43.24 | 2.12 | 0.00% |
| Thermo Fisher Scientific (TMO) | 248.08B | 35.31 | 4.53 | 0.27% |
| Danaher (DHR) | 155.03B | 36.12 | 2.89 | 0.69% |
| IDEXX Laboratories Inc (IDXX) | 53.28B | 45.57 | 28.50 | 0.00% |
| Agilent Technologies (A) | 48.04B | 33.61 | 6.52 | 0.59% |
| Waters (WAT) | 43.29B | 184.29 | 2.83 | 0.00% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 5.5% below Morningstar's fair value estimate.
Fair value
Castle Biosciences Inc receives a 3-star quantitative star rating, reflecting our opinion that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a minor 3% discount to our quantitative fair value estimate of $34.68 per share; however, caution is warranted due to this estimate's high uncertainty rating.
The company's solid growth bolsters our estimated valuation. Consistent revenue and earnings growth indicates a company's potential for increased market share and profitability. For example, the firm's revenue 3-year growth of 23.6% ranks in the top 20% compared with global peers. Robust trailing three-year revenue growth portends a favorable future trajectory, which contributes to our view that shares are cheap.
Alternatively, the company's lack of profitability is potentially concerning. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's earnings yield of 1.0%, a core component of profitability, sits in the bottom 40% globally. The earnings generated by the company relative to its share price is concerning, which, despite our favorable price/fair value ratio, is a negative attribute.
In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance bodes well for future returns in light of other contributors to our model.
Economic moat
With its quantitative economic moat rating of none, this business is unlikely to consistently outearn its cost of capital without structural protection from competition. However, its financial health score is strong, suggesting that the company should be well positioned to weather tough times.
By Quantitative Equity Report
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Castle Biosciences discussion 0 comments